Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.

This distinction between true value and value traps can challenge even the most skilled investors. Luckily for you, we started StockStory to help you uncover exceptional companies. That said, here is one value stock offering a compelling risk-reward profile and two climbing an uphill battle.

Two Value Stocks to Sell:

JLL (JLL)

Forward P/E Ratio: 13.6x

Founded in 1999 through the merger of Jones Lang Wootton and LaSalle Partners, JLL (NYSE: JLL) is a company specializing in real estate advisory and investment management services.

Why Should You Sell JLL?

1. Scale is a double-edged sword because it limits the company’s growth potential compared to its smaller competitors, as reflected in its below-average annual revenue increases of 9.5% for the last five years
2. Free cash flow margin is expected to remain in place over the coming year
3. Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value

JLL is trading at $296.46 per share, or 13.6x forward P/E. Check out our free in-depth research report to learn more about why JLL doesn’t pass our bar.

Charles River Laboratories (CRL)

Forward P/E Ratio: 14.9x

Named after the Massachusetts river where it was founded in 1947, Charles River Laboratories (NYSE: CRL) provides non-clinical drug development services, research models, and manufacturing support to pharmaceutical and biotechnology companies.

Why Are We Hesitant About CRL?

1. Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
2. Estimated sales for the next 12 months are flat and imply a softer demand environment
3. Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions

At $165.18 per share, Charles River Laboratories trades at 14.9x forward P/E. Dive into our free research report to see why there are better opportunities than CRL.

One Value Stock to Buy:

Micron (MU)

Forward P/E Ratio: 4.2x

Founded in the basement of a Boise, Idaho dental office in 1978, Micron (NASDAQ: MU) is a leading provider of memory chips used in thousands of devices across mobile, data centers, industrial, consumer, and automotive markets.

Why Is MU a Top Pick?

1. Market share has increased this cycle as its 78.2% annual revenue growth over the last two years was exceptional
2. Excellent operating margin of 38.3% highlights the efficiency of its business model, and it turbocharged its profits by achieving some fixed cost leverage
3. Additional sales over the last five years increased its profitability as the 43% annual growth in its earnings per share outpaced its revenue

Micron’s stock price of $356.40 implies a valuation ratio of 4.2x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.

High-Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.